A Bayesian-frequentist two-stage single-arm phase II clinical trial design

Gaohong Dong, Weichung Joe Shih, Dirk Moore, Hui Quan, Stephen Marcella

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It is well-known that both frequentist and Bayesian clinical trial designs have their own advantages and disadvantages. To have better properties inherited from these two types of designs, we developed a Bayesian-frequentist two-stage single-arm phase II clinical trial design. This design allows both early acceptance and rejection of the null hypothesis (H 0 ). The measures (for example probability of trial early termination, expected sample size, etc.) of the design properties under both frequentist and Bayesian settings are derived. Moreover, under the Bayesian setting, the upper and lower boundaries are determined with predictive probability of trial success outcome. Given a beta prior and a sample size for stage I, based on the marginal distribution of the responses at stage I, we derived Bayesian Type I and Type II error rates. By controlling both frequentist and Bayesian error rates, the Bayesian-frequentist two-stage design has special features compared with other two-stage designs.

Original languageEnglish (US)
Pages (from-to)2055-2067
Number of pages13
JournalStatistics in Medicine
Volume31
Issue number19
DOIs
StatePublished - Aug 30 2012

Fingerprint

Phase II Clinical Trials
Clinical Trials
Sample Size
Two-stage Design
Error Rate
Bayesian Design
Early Termination
Type II error
Marginal Distribution
Rejection
Null hypothesis
Design

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Statistics and Probability

Cite this

Dong, Gaohong ; Shih, Weichung Joe ; Moore, Dirk ; Quan, Hui ; Marcella, Stephen. / A Bayesian-frequentist two-stage single-arm phase II clinical trial design. In: Statistics in Medicine. 2012 ; Vol. 31, No. 19. pp. 2055-2067.
@article{29571a33509948ec9b6d436d3e115e44,
title = "A Bayesian-frequentist two-stage single-arm phase II clinical trial design",
abstract = "It is well-known that both frequentist and Bayesian clinical trial designs have their own advantages and disadvantages. To have better properties inherited from these two types of designs, we developed a Bayesian-frequentist two-stage single-arm phase II clinical trial design. This design allows both early acceptance and rejection of the null hypothesis (H 0 ). The measures (for example probability of trial early termination, expected sample size, etc.) of the design properties under both frequentist and Bayesian settings are derived. Moreover, under the Bayesian setting, the upper and lower boundaries are determined with predictive probability of trial success outcome. Given a beta prior and a sample size for stage I, based on the marginal distribution of the responses at stage I, we derived Bayesian Type I and Type II error rates. By controlling both frequentist and Bayesian error rates, the Bayesian-frequentist two-stage design has special features compared with other two-stage designs.",
author = "Gaohong Dong and Shih, {Weichung Joe} and Dirk Moore and Hui Quan and Stephen Marcella",
year = "2012",
month = "8",
day = "30",
doi = "10.1002/sim.5330",
language = "English (US)",
volume = "31",
pages = "2055--2067",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "19",

}

A Bayesian-frequentist two-stage single-arm phase II clinical trial design. / Dong, Gaohong; Shih, Weichung Joe; Moore, Dirk; Quan, Hui; Marcella, Stephen.

In: Statistics in Medicine, Vol. 31, No. 19, 30.08.2012, p. 2055-2067.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Bayesian-frequentist two-stage single-arm phase II clinical trial design

AU - Dong, Gaohong

AU - Shih, Weichung Joe

AU - Moore, Dirk

AU - Quan, Hui

AU - Marcella, Stephen

PY - 2012/8/30

Y1 - 2012/8/30

N2 - It is well-known that both frequentist and Bayesian clinical trial designs have their own advantages and disadvantages. To have better properties inherited from these two types of designs, we developed a Bayesian-frequentist two-stage single-arm phase II clinical trial design. This design allows both early acceptance and rejection of the null hypothesis (H 0 ). The measures (for example probability of trial early termination, expected sample size, etc.) of the design properties under both frequentist and Bayesian settings are derived. Moreover, under the Bayesian setting, the upper and lower boundaries are determined with predictive probability of trial success outcome. Given a beta prior and a sample size for stage I, based on the marginal distribution of the responses at stage I, we derived Bayesian Type I and Type II error rates. By controlling both frequentist and Bayesian error rates, the Bayesian-frequentist two-stage design has special features compared with other two-stage designs.

AB - It is well-known that both frequentist and Bayesian clinical trial designs have their own advantages and disadvantages. To have better properties inherited from these two types of designs, we developed a Bayesian-frequentist two-stage single-arm phase II clinical trial design. This design allows both early acceptance and rejection of the null hypothesis (H 0 ). The measures (for example probability of trial early termination, expected sample size, etc.) of the design properties under both frequentist and Bayesian settings are derived. Moreover, under the Bayesian setting, the upper and lower boundaries are determined with predictive probability of trial success outcome. Given a beta prior and a sample size for stage I, based on the marginal distribution of the responses at stage I, we derived Bayesian Type I and Type II error rates. By controlling both frequentist and Bayesian error rates, the Bayesian-frequentist two-stage design has special features compared with other two-stage designs.

UR - http://www.scopus.com/inward/record.url?scp=84864020956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864020956&partnerID=8YFLogxK

U2 - 10.1002/sim.5330

DO - 10.1002/sim.5330

M3 - Article

C2 - 22415966

AN - SCOPUS:84864020956

VL - 31

SP - 2055

EP - 2067

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 19

ER -